Antipsychotic Drugs Market Size, Share, Trends, Growth Outlook

Antipsychotic Drugs Market is estimated to increase at a growth rate of 7.5% CAGR over the forecast period from 2024 to 2030.

The Antipsychotic Drugs Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Class Type, First Generation, Second Generation, Third generation), By Application (Schizophrenia, Bipolar disorders, Dementia, Unipolar Depression, Others).

An Introduction to Antipsychotic Drugs Market in 2024

The Antipsychotic Drugs Market in 2024 is witnessing significant growth, driven by the increasing prevalence of mental health disorders, expanding indications for antipsychotic therapies, and advancements in drug development to address diverse psychiatric symptoms and treatment-resistant conditions. Mental health disorders, including schizophrenia, bipolar disorder, and major depressive disorder, represent a significant burden on individuals, families, and healthcare systems, driving the demand for effective antipsychotic medications to manage psychotic symptoms, mood disturbances, and cognitive deficits. With advancements in pharmacology, receptor targeting, and personalized medicine approaches, the market offers a range of antipsychotic drugs, including first-generation and second-generation agents, atypical antipsychotics, and long-acting injectable formulations, tailored to specific symptom profiles, treatment responses, and side effect profiles. Moreover, emerging research into novel drug targets, adjunctive therapies, and digital therapeutics holds promise for further optimizing antipsychotic treatment strategies and improving long-term outcomes for patients with severe mental illness across different stages of the disease continuum.

Antipsychotic Drugs Market Trend: Increasing Adoption of Long-Acting Injectable Antipsychotics

A prominent trend in the Antipsychotic Drugs market is the growing adoption of long-acting injectable (LAI) antipsychotics for the management of schizophrenia and other psychiatric disorders. LAI antipsychotics offer several advantages over oral formulations, including improved medication adherence, reduced risk of relapse, and enhanced therapeutic efficacy due to consistent plasma drug levels. Healthcare providers are increasingly recognizing the benefits of LAI antipsychotics in optimizing treatment outcomes and minimizing the burden of non-adherence, leading to greater acceptance and incorporation of LAI formulations into clinical practice guidelines and treatment algorithms. As patients and clinicians seek options for long-term symptom control and relapse prevention in schizophrenia management, the demand for LAI antipsychotics is expected to continue rising, driving market growth and innovation in sustained-release formulations and delivery systems.

Antipsychotic Drugs Market Driver: Growing Prevalence of Schizophrenia and Psychotic Disorders

A key driver fueling the Antipsychotic Drugs market is the growing prevalence of schizophrenia and psychotic disorders worldwide. Schizophrenia is a severe and chronic mental illness characterized by psychotic symptoms such as hallucinations, delusions, disorganized thinking, and impaired social functioning. Psychotic disorders encompass a spectrum of conditions marked by disturbances in perception, cognition, and behavior, affecting individuals' ability to function in daily life. With increasing recognition and diagnosis of psychotic disorders, coupled with population growth and aging demographics, the global burden of schizophrenia and related conditions continues to escalate, driving the demand for antipsychotic medications as first-line treatment options for symptom management and relapse prevention. As healthcare systems strive to address the unmet needs of patients with severe mental illness and improve access to effective pharmacological interventions, the demand for antipsychotic drugs is expected to grow, stimulating market expansion and research efforts focused on novel drug development and therapeutic innovations.

Antipsychotic Drugs Market Opportunity: Expansion of Indications Beyond Schizophrenia

An opportunity in the Antipsychotic Drugs market lies in the expansion of indications beyond schizophrenia to address a broader range of psychiatric conditions and treatment-resistant cases. While antipsychotic medications are primarily indicated for schizophrenia and related psychotic disorders, emerging evidence suggests potential therapeutic benefits in other mental health conditions, such as bipolar disorder, major depressive disorder (MDD), and autism spectrum disorder (ASD), among others. Additionally, there is growing interest in exploring the use of antipsychotics as adjunctive therapy in treatment-resistant cases and for managing specific symptoms, such as agitation, aggression, and mood instability, across different psychiatric diagnoses. By leveraging the diverse pharmacological properties of antipsychotic drugs and conducting rigorous clinical research to evaluate their efficacy and safety in various clinical populations, pharmaceutical companies have the opportunity to expand their product portfolios and pursue new indications, addressing unmet medical needs and diversifying revenue streams in the evolving landscape of mental healthcare.

Antipsychotic Drugs Market Segmentation

By Class Type
First Generation
-Haldo
-Navane
-Others
Second Generation
-Invega
-Latuda
-Seroquel
-Risperdal
-Zyprexa
-Geodon
-Others
Third generation
-Abilify
By Application
Schizophrenia
Bipolar disorders
Dementia
Unipolar Depression
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Antipsychotic Drugs Market Companies

AbbVie Inc
Acadia Pharmaceuticals Inc
Alkermes
AstraZeneca plc
Eli Lily and Company
GlaxoSmithKline plc
H. Lundbeck A/S
Intra-Cellular Therapies Inc
Johnson & Johnson
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
Sumitomo Pharma Co. Ltd
Teva Pharmaceutical Industries Ltd

 

 

Reasons to Buy the Antipsychotic Drugs Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Antipsychotic Drugs Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Antipsychotic Drugs Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Antipsychotic Drugs Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Antipsychotic Drugs Market Size Outlook, $ Million, 2021 to 2030
3.2 Antipsychotic Drugs Market Outlook by Type, $ Million, 2021 to 2030
3.3 Antipsychotic Drugs Market Outlook by Product, $ Million, 2021 to 2030
3.4 Antipsychotic Drugs Market Outlook by Application, $ Million, 2021 to 2030
3.5 Antipsychotic Drugs Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Antipsychotic Drugs Market Industry
4.2 Key Market Trends in Antipsychotic Drugs Market Industry
4.3 Potential Opportunities in Antipsychotic Drugs Market Industry
4.4 Key Challenges in Antipsychotic Drugs Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Antipsychotic Drugs Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Antipsychotic Drugs Market Outlook By Segments
7.1 Antipsychotic Drugs Market Outlook by Segments
By Class Type
First Generation
-Haldo
-Navane
-Others
Second Generation
-Invega
-Latuda
-Seroquel
-Risperdal
-Zyprexa
-Geodon
-Others
Third generation
-Abilify
By Application
Schizophrenia
Bipolar disorders
Dementia
Unipolar Depression
Others

8 North America Antipsychotic Drugs Market Analysis And Outlook To 2030
8.1 Introduction to North America Antipsychotic Drugs Markets in 2024
8.2 North America Antipsychotic Drugs Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Antipsychotic Drugs Market size Outlook by Segments, 2021-2030
By Class Type
First Generation
-Haldo
-Navane
-Others
Second Generation
-Invega
-Latuda
-Seroquel
-Risperdal
-Zyprexa
-Geodon
-Others
Third generation
-Abilify
By Application
Schizophrenia
Bipolar disorders
Dementia
Unipolar Depression
Others

9 Europe Antipsychotic Drugs Market Analysis And Outlook To 2030
9.1 Introduction to Europe Antipsychotic Drugs Markets in 2024
9.2 Europe Antipsychotic Drugs Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Antipsychotic Drugs Market Size Outlook By Segments, 2021-2030
By Class Type
First Generation
-Haldo
-Navane
-Others
Second Generation
-Invega
-Latuda
-Seroquel
-Risperdal
-Zyprexa
-Geodon
-Others
Third generation
-Abilify
By Application
Schizophrenia
Bipolar disorders
Dementia
Unipolar Depression
Others

10 Asia Pacific Antipsychotic Drugs Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Antipsychotic Drugs Markets in 2024
10.2 Asia Pacific Antipsychotic Drugs Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Antipsychotic Drugs Market size Outlook by Segments, 2021-2030
By Class Type
First Generation
-Haldo
-Navane
-Others
Second Generation
-Invega
-Latuda
-Seroquel
-Risperdal
-Zyprexa
-Geodon
-Others
Third generation
-Abilify
By Application
Schizophrenia
Bipolar disorders
Dementia
Unipolar Depression
Others

11 South America Antipsychotic Drugs Market Analysis And Outlook To 2030
11.1 Introduction to South America Antipsychotic Drugs Markets in 2024
11.2 South America Antipsychotic Drugs Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Antipsychotic Drugs Market size Outlook by Segments, 2021-2030
By Class Type
First Generation
-Haldo
-Navane
-Others
Second Generation
-Invega
-Latuda
-Seroquel
-Risperdal
-Zyprexa
-Geodon
-Others
Third generation
-Abilify
By Application
Schizophrenia
Bipolar disorders
Dementia
Unipolar Depression
Others

12 Middle East And Africa Antipsychotic Drugs Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Antipsychotic Drugs Markets in 2024
12.2 Middle East and Africa Antipsychotic Drugs Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Antipsychotic Drugs Market size Outlook by Segments, 2021-2030
By Class Type
First Generation
-Haldo
-Navane
-Others
Second Generation
-Invega
-Latuda
-Seroquel
-Risperdal
-Zyprexa
-Geodon
-Others
Third generation
-Abilify
By Application
Schizophrenia
Bipolar disorders
Dementia
Unipolar Depression
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
Acadia Pharmaceuticals Inc
Alkermes
AstraZeneca plc
Eli Lily and Company
GlaxoSmithKline plc
H. Lundbeck A/S
Intra-Cellular Therapies Inc
Johnson & Johnson
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
Sumitomo Pharma Co. Ltd
Teva Pharmaceutical Industries Ltd

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Class Type
First Generation
-Haldo
-Navane
-Others
Second Generation
-Invega
-Latuda
-Seroquel
-Risperdal
-Zyprexa
-Geodon
-Others
Third generation
-Abilify
By Application
Schizophrenia
Bipolar disorders
Dementia
Unipolar Depression
Others